LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.

Photo by nci from unsplash

TPS5612Background: Patients with platinum-resistant ovarian cancer, following ≥3 lines of chemotherapy have limited treatment options. NUC-1031, a phosphoramidate transformation of gemcitabine, is ... Click to show full abstract

TPS5612Background: Patients with platinum-resistant ovarian cancer, following ≥3 lines of chemotherapy have limited treatment options. NUC-1031, a phosphoramidate transformation of gemcitabine, is ...

Keywords: resistant ovarian; nuc 1031; ovarian cancer; platinum resistant; patients platinum

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.